Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial.
Cadorna-Carlos JB, Nolan T, Borja-Tabora CF, Santos J, Montalban MC, de Looze FJ, Eizenberg P, Hall S, Dupuy M, Hutagalung Y, Pépin S, Saville M. Cadorna-Carlos JB, et al. Among authors: pepin s. Vaccine. 2015 May 15;33(21):2485-92. doi: 10.1016/j.vaccine.2015.03.065. Epub 2015 Apr 2. Vaccine. 2015. PMID: 25843270 Free article. Clinical Trial.
Quadrivalent inactivated influenza vaccine (VaxigripTetra™).
Gresset-Bourgeois V, Leventhal PS, Pepin S, Hollingsworth R, Kazek-Duret MP, De Bruijn I, Samson SI. Gresset-Bourgeois V, et al. Among authors: pepin s. Expert Rev Vaccines. 2018 Jan;17(1):1-11. doi: 10.1080/14760584.2018.1407650. Epub 2017 Nov 27. Expert Rev Vaccines. 2018. PMID: 29157068 Free article. Review.
Efficacy, immunogenicity, and safety of a quadrivalent inactivated influenza vaccine in children aged 6-35 months: A multi-season randomised placebo-controlled trial in the Northern and Southern Hemispheres.
Pepin S, Dupuy M, Borja-Tabora CFC, Montellano M, Bravo L, Santos J, de Castro JA, Rivera-Medina DM, Cutland C, Ariza M, Diez-Domingo J, Gonzalez CD, Martinón-Torres F, Papadopoulou-Alataki E, Theodoriadou M, Kazek-Duret MP, Gurunathan S, De Bruijn I; GQM05 Study Group. Pepin S, et al. Vaccine. 2019 Mar 22;37(13):1876-1884. doi: 10.1016/j.vaccine.2018.11.074. Epub 2018 Dec 14. Vaccine. 2019. PMID: 30558818 Free article. Clinical Trial.
Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the Northern and Southern Hemispheres.
Pepin S, Samson SI, Alvarez FP, Dupuy M, Gresset-Bourgeois V, De Bruijn I. Pepin S, et al. Vaccine. 2019 Mar 22;37(13):1885-1888. doi: 10.1016/j.vaccine.2019.01.059. Epub 2019 Feb 8. Vaccine. 2019. PMID: 30745147 Free article. Clinical Trial.
Immunogenicity and safety of a multi-dose quadrivalent inactivated influenza vaccine in individuals aged 6 months to 17 years: a randomized phase III trial.
Ojeda J, Arredondo JL, Salcedo P, Paredes-Paredes M, Dupuy M, Petit C, Chabanon AL, Rivas E, Gurunathan S, De Bruijn I, Pepin S. Ojeda J, et al. Among authors: pepin s. Hum Vaccin Immunother. 2020 Jun 2;16(6):1380-1384. doi: 10.1080/21645515.2019.1697595. Epub 2019 Dec 20. Hum Vaccin Immunother. 2020. PMID: 31810418 Free PMC article. Clinical Trial.
Effectiveness of the quadrivalent high-dose influenza vaccine for prevention of cardiovascular and respiratory events in people aged 65 years and above: Rationale and design of a real-world pragmatic randomized clinical trial.
Hollingsworth R, Palmu A, Pepin S, Dupuy M, Shrestha A, Jokinen J, Syrjänen R, Nealon J, Samson S, De Bruijn I. Hollingsworth R, et al. Among authors: pepin s. Am Heart J. 2021 Jul;237:54-61. doi: 10.1016/j.ahj.2021.03.007. Epub 2021 Mar 13. Am Heart J. 2021. PMID: 33722585 Free article. Clinical Trial.
Corrigendum to "Impact of a quadrivalent inactivated influenza vaccine on influenza-associated complications and health care use in children aged 6 to 35 months: Analysis of data from a phase III trial in the northern and southern Hemispheres" [Vaccine 37(13) (2019) 1885-1888].
Pepin S, Samson SI, Alvarez FP, Dupuy M, Gresset-Bourgeois V, De Bruijn I. Pepin S, et al. Vaccine. 2023 Jan 9;41(2):621. doi: 10.1016/j.vaccine.2022.11.059. Epub 2022 Dec 9. Vaccine. 2023. PMID: 36509639 Free article. No abstract available.
80 results